Two-in-One antibodies with dual action Fabs

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 400-405

  Eigenbrot, Charles ^a   Fuh, Germaine ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BH1 44; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HER3 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; TRASTUZUMAB; TWO IN ONE DUAL ACTION FABS; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; NONHUMAN; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIBODIES, BISPECIFIC; DRUG DISCOVERY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MUTAGENESIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 84878834722     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.015     Document Type: Review

References (39)

1. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
2. Sundberg E.J., Mariuzza R.A. Molecular recognition in antibody-antigen complexes. Adv Protein Chem 2002, 61:119-160.
3. Notkins A.L. Polyreactivity of antibody molecules. Trends Immunol 2004, 25:174-179.
4. Foote J. Isomeric antibodies. Science 2003, 299:1327-1328.
5. James L.C., Roversi P., Tawfik D.S. Antibody multispecificity mediated by conformational diversity. Science 2003, 299:1362-1367.
6. Sethi D.K., Agarwal A., Manivel V., Rao K.V., Salunke D.M. Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity 2006, 24:429-438.
7. Kampa-Schittenhelm K.M., Heinrich M.C., Akmut F., Dohner H., Dohner K., Schittenhelm M.M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013, 12:19.
8. Bowles D.W., Kessler E.R., Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc) 2011, 47:857-868.
9. Kramer A., Keitel T., Winkler K., Stocklein W., Hohne W., Schneider-Mergener J. Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 1997, 91:799-809.
10. Trinh C.H., Hemmington S.D., Verhoeyen M.E., Phillips S.E. Antibody fragment Fv4155 bound to two closely related steroid hormones: the structural basis of fine specificity. Structure 1997, 5:937-948.
11. Arevalo J.H., Taussig M.J., Wilson I.A. Molecular basis of crossreactivity and the limits of antibody-antigen complementarity. Nature 1993, 365:859-863.
12. Lee C.V., Hymowitz S.G., Wallweber H.J., Gordon N.C., Billeci K.L., Tsai S.P., Compaan D.M., Yin J., Gong Q., Kelley R.F., et al. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 2006, 108:3103-3111.
13. Fuh G., Wu P., Liang W.C., Ultsch M., Lee C.V., Moffat B., Wiesmann C. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006, 281:6625-6631.
14. Dall'Acqua W., Goldman E.R., Eisenstein E., Mariuzza R.A. A mutational analysis of the binding of two different proteins to the same antibody. Biochemistry 1996, 35:9667-9676.
15. Mohan S., Kourentzi K., Schick K.A., Uehara C., Lipschultz C.A., Acchione M., Desantis M.E., Smith-Gill S.J., Willson R.C. Association energetics of cross-reactive and specific antibodies. Biochemistry 2009, 48:1390-1398.
16. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
17. Ekiert D.C., Wilson I.A. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol 2012, 2:134-141.
18. Keitel T., Kramer A., Wessner H., Scholz C., Schneider-Mergener J., Hohne W. Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity. Cell 1997, 91:811-820.
19. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
20. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
21. Parren P.W., Burton D.R. Immunology. Two-in-one designer antibodies. Science 2009, 323:1567-1568.
22. Bostrom J., Haber L., Koenig P., Kelley R.F., Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS ONE 2011, 6:e17887.
23. Kelley R.F., O'Connell M.P. Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993, 32:6828-6835.
24. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
25. Kelley R.F., O'Connell M.P., Carter P., Presta L., Eigenbrot C., Covarrubias M., Snedecor B., Bourell J.H., Vetterlein D. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. Biochemistry 1992, 31:5434-5441.
26. Eigenbrot C., Randal M., Presta L., Carter P., Kossiakoff A.A. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 1993, 229:969-995.
27. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21:177-184.
28. Jones R.L., Smith I.E. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006, 7:869-874.
29. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
30. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012, 12:553-563.
31. Grothey A. EGFR antibodies in colorectal cancer: where do they belong?. J Clin Oncol 2010, 28:4668-4670.
32. Engelman J.A., Janne P.A. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med 2005, 26:314-322.
33. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005, 102:3788-3793.
34. Buck E., Eyzaguirre A., Haley J.D., Gibson N.W., Cagnoni P., Iwata K.K. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006, 5:2051-2059.
35. Kontermann R.E. Bispecific Antibodies 2011, Springer.
36. Taylor R.J., Chan S.L., Wood A., Voskens C.J., Wolf J.S., Lin W., Chapoval A., Schulze D.H., Tian G., Strome S.E. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009, 58:997-1006.
37. Lee C.V., Liang W.C., Dennis M.S., Eigenbrot C., Sidhu S.S., Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004, 340:1073-1093.
38. Lee C.V., Sidhu S.S., Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods 2004, 284:119-132.
39. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.